[1] BONASIO R,TU S,REINBERG D.Molecular signals of epigenetic states［J］.Science,2010,330(6004):612-616.
[2] HULL EE,MONTGOMERY MR,LEYVA KJ.HDAC inhibitors as epigenetic regulators of the immune system:Impacts on cancer therapy and inflammatory diseases［J］.Biomed Res Int,2016,2016:8797206.
[3] DOKMANOVIC M,CLARKE C,MARKS PA.Histone deacetylase inhibitors:Overview and perspectives［J］.Mol Cancer Res,2007,5(10):981-989.
[4] SETO E,YOSHIDA M.Erasers of histone acetylation:the histone deacetylase enzymes［J］.Cold Spring Harb Perspect Biol,2014,6(4):a018713.
[5] CHENG Y,HE C,WANG M,et al.Targetin gepigenetic regulators for cancer therapy:Mechanisms and advances in clinical trials［J］.Signal Transduct Target Ther,2019,4:62.
[6] SERMER D,PASQUALUCCI L,WENDEL HG,et al.Emerging epigenetic-modulating therapies in lymphoma［J］.Nat Rev Clin Oncol,2019,16(8):494-507.
[7] OLSEN EA,KIM YH,KUZEL TM,et al.Phase IIB multicenter trial of vorinostat in patients with persistent,progressive,or treatment refractory cutaneous t-cell lymphoma［J］.J Clin Oncol,2007,25(21):3109-3115.
[8] PIEKARZ RL,FRYE R,PRINCE HM,et al.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma［J］.Blood,2011,117(22):5827-5834.
[9] WEST AC,JOHNSTONE RW.New and emerging HDAC inhibitors for cancer treatment［J］.J Clin Invest,2014,124(1):30-39.
[10]LAUBACH JP,MOREAU P,SAN-MIGUEL JF,et al.Panobinostat for the treatment of multiple myeloma［J］.Clin Cancer Res,2015,21(21):4767-4773.
[11]THOMPSON CA.Belinostat approved for use in treating rare lymphoma［J］.Am J Health Syst Pharm,2014,71(16):1328.
[12]PAN DS,YANG QJ,FU X,et al.Discovery of an orally active subtype-selective HDAC inhibitor, chidamide,as an epigenetic modulator for cancer treatment［J］.Medchemcomm,2014,5:1789-1796.
[13]SHI Y,DONG M,HONG X,et al.Results from a multicenter,open-label,pivotal phase II study of chidamide in relapsed or refractory pe-ripheral T-cell lymphoma［J］.Ann Oncol,2015,26(8):1766-1771.
[14]GONG K,XIE J,YI H,et al.CS055(Chidamide/HBI-8000),a novel histone deacetylase inhibitor,induces G1 arrest,ROS-dependent apoptosis and differentiation in human leukaemia cells［J］.BiochemJ,2012,443(3):735-746.
[15] GUAN W,JING Y,DOU L,et al.Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia［J］.Leuk Lymphoma,2020,61(4):855-861.
[16] LIU W,ZHAO D,LIU T,et al.A multi-center,real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China［J］.Front Oncol,2021,11:750323-750327.
[17] ZHANG W,SU L,LIU L,et al.The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma:a prospective,multicenter,single arm,phase 1b/2 study［J］.Cancer Biol Med,2021,18(3):841-848.
[18] WANG J,SU N,FANG Y,et al.Comparison of chemotherapy combined with chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma［J］.Front Immunol, 2022,13:835103.
[19]WANG Y,ZHANG M,SONG W,et al.Chidamide plus prednisone,etoposide,and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population:a multicenter phase II trial［J］.Am J Hematol,2022,97(5):623-629.
[20] RIDWANSYAH H,WIJAYA I,BASHARI MH,et al.The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma:An updated systematic review［J］.Biomol Biomed,2023,23(5):727-739.
[21] SUN Y,GAO Y,CHEN J,et al.CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma［J］.Cancer Lett,2021,521:268-280.
[22]WANG Y,XUE H,SONG W,et al.Chidamide with PEL regimen(prednisone,etoposide,lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-cell lymphoma-results of a single center,retrospective cohort in China［J］.Hematol Oncol, 2022,40(4):617-625.
[23] GUAN XW, WANG HQ, BAN WW, et al.Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20［J］.Cell Death Dis,2020,11(1):20.
[24]CHEN J,ZUO Z,GAO Y,et al.Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide［J］.Clin Epigenetics,2023,15(1):19.
[25]SONG W,CHEN Z,SHI C,et al.Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma［J］.Hematol Oncol,2023,41(2):257-266.
[26]JI J,LIU Z,KUANG P,et al.A new conditioning regimen with chidamide,cladribine,gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas［J］.Int J Cancer,2021,149(12):2075-2082.
[27]ZENG Q,ZHANG H,KUANG P,et al.A novel conditioning regimen of chidamide,cladribine,gemcitabine,and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma［J］.Front Oncol,2023,13:1143556.
[28] ZHAO S,GUO J,ZHAO Y,et al.Chidamide,a novel histone deacetylaseinhibitor,inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling［J］.Am J Transl Res,2016,8(7):3169-3178.
[29] WANG JD,XU JQ,LONG ZJ,et al.Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML［J］.Clin Transl Oncol,2023,25(6):1805-1820.
[30] CHEN K,YANG Q,ZHA J,et al.Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia［J］.Cell Death Dis,2020,11(9):778.
[31] DENG M,XIAO H,PENG H,et al.Chidamide works synergistically with Dasatinib by inducing cell?Cycle arrest and apoptosis in acute myeloid leukemia cells［J］.Mol Cell Biochem,2023,478(4):851-860.
[32] GU S,HOU Y,DOVAT K,et al.Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia［J］.Exp Hematol Oncol,2023,12(1):23.
[33] LI Z,ZHANG J,ZHOU M,et al.Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro［J］.Oncol Rep,2022,47(4):66.
[34] MAO J,LI S,ZHAO H,et al.Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines［J］.Am J Transl Res,2018,10(8):2567-2578.
[35] LI Q,HUANG JC,LIAO DY,et al.Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating PERP［J］.Am J Transl Res,2020,12(7):3461-3475.
[36] WANG L,LUO J,CHEN G,et al.Chidamide,decitabine,cytarabine,aclarubicin,and granulocyte colony-stimulatingfactor(CDCAG)in patients with relapsed/refractory acute myeloid leukemia:a single-arm,phase 1/2 study［J］.Clin Epigenetics,2020,12(1):132.
[37] YIN J,WAN CL,ZHANG L,et al.A phase II trial of the double epigenetic priming regimen including Chidamide and decitabine for relapsed/refractory acute myeloid leukemia［J］.Front Oncol,2021,11:726926.
[38] ZHANG B,PEI Z,WANG H,et al.Chidamide and decitabine in combination with a HAG priming regimen for acute myeloid leukemia with TP53 mutation［J］.Acta Med Okayama,2022,76(1):63-70.
[39] WANG H,LIU YC,ZHU CY,et al.Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway［J］.J Exp Clin Cancer Res,2020,39(1):278.
[40] LUN Y,YANG JJ,WU Y.Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy［J］.J Clin Pharm Ther,2017,42(6):786-789.
[41] XI M,GUO S,BAYIN C,et al.Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia［J］.Front Med,2021,16(3):442-458.
[42] CHI Z,GAO H,LIU H,et al.Chidamide induces necroptosis via regulation of c-FLIPL expression in Jurkat and HUT-78 cells［J］.Mol Med Rep,2020,21(2):936-944.
[43] LI XY,HAN XW,HUANG K,et al.Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblasticleukemia:A real-world prospective study［J］.Front Med(Lausanne),2023,10:1096529.
[44] ZHAO L,LYU C,SUN L,et al.Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL［J］.Invest New Drugs,2021,39(4):961-970.
[45] JIANG D,ZHANG K,ZHU Y,et al.Chidamide-induced accumulation of reactive oxygen species increases lenalidomide sensitivity against multiple myeloma cells［J］.Onco Targets Ther,2021,14:4061-4075.
[46] YUAN XG,HUANG YR,YU T,et al.Chidamide,a histone deacetylase inhibitor,induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner［J］.Oncol Lett,2019,18(1):411-419.
[47] CAO L,CHEN Q,GU H,et al.Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression［J］.Clin Epigenet,2022,14(1):84.
[48] LIU Z,JING Q,WANG Y,et al.The short-term effect of histone deacetylase inhibitors,chidamide and valproic acid,on the NF-κB pathway in multiple myeloma cells［J］.Int J Mol Med,2019,43(1):285-293.
[49] SUN Y,LI J,XU Z,et al.Chidamide,a novel histone deacetylase inhibitor,inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A［J］.Am J Cancer Res,2019,9(3):574-584.
[50] SUN Y,XU Z,JIANG J,et al.High expression of succinate dehydrogenase subunit A which is regulated by histone acetylation,acts as a good prognostic factor of multiple myeloma patients［J］.Front Oncol,2020,10:563666-563713.
[51] HE J,CHEN Q,GU H,et al.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease［J］.Haematologica,2018,103(8):1369-1379.
[52] XU L,FENG J,TANG H,et al.Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib［J］.Cell Death Dis,2020,11(4):297.
[53] HE Y,JIANG D,ZHANG K,et al.Chidamide,a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy［J］.J Cancer,2021,12(20):6198-6208.
[54] WANG DY,CUI YS,LIU YZ,et al.Successful treatment of one case with relapsed refractory multiple myeloma bychidamide in combination with bortezomib and dexamethasone［J］.Chinese Journal of Hematology,2016,37(6):463.
[55] YANG Y,FU LJ,CHEEN CM,et al.Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14):a case report［J］.World J Clin Cases,2021,9(5):1175-1183.